• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

    11.39 -0.03 (-0.26%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,101,032
    Open 11.37
    Bid (Size) 11.39 (900)
    Ask (Size) 11.65 (200)
    Prev. Close 11.42
    Today's Range 10.83 - 11.48
    52wk Range 2.600 - 16.96
    Shares Outstanding 67,176,067
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
    A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
    Via The Motley Fool
    News headline image
    Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
    Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
    Via The Motley Fool

    Performance

    YTD
    -0.3%
    -0.3%
    1 Month
    -16.7%
    -16.7%
    3 Month
    -10.2%
    -10.2%
    6 Month
    +68.5%
    +68.5%
    1 Year
    +190.6%
    +190.6%

    More News

    Read More
    News headline image
    Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
    Via The Motley Fool
    News headline image
    Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
    From Rosen Law Firm
    Via Business Wire
    News headline image
    Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗
    Via Chartmill
    News headline image
    Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire

    Frequently Asked Questions

    Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
    Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
    What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 11.39
    When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 01/05/26 04:00 PM ET
    What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 765.14M
    How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
    Amylyx Pharmaceuticals, Inc. - Common Stock has 765M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.